Figure 3.
Sankey diagram demonstrating changes in ERS/ESC 2022 simplified four-strata risk category on addition of third sequential drug. Interestingly, no patient remained in high-risk category after addition of third sequential drug.
ERS/ESC, European Respiratory Society/European Society of Cardiology.